Early Clinical
Early phase development services that will enable informed decision making for your drug development programme.
Innovative early clinical solutions that will advance your drug development strategy
-
6
Clinical research units across Europe and the USA -
894
Early phase clinical trials over the last 5 years -
32,600
Healthy volunteers and patients targeted
ICON is committed to the highest standards of excellence and scientific expertise in early clinical drug development.
We have extensive experience in the design, conduct, and interpretation of early phase first-in-human and proof of concept studies, providing the full suite of clinical pharmacology studies, all elements of a regulatory package programme, and translational early efficacy indication solutions in a range of study types including:
|
|
|
ICON’s early clinical services deliver full visibility and control to meet the requirements of increasingly complex clinical trial requirements. Our dedicated early phase specialists will engage with you to develop a trial that is best for your compound. Together we will build a tailored approach that leverages our asset development consulting, clinical pharmacology expertise, extensive research facilities, early phase operational experience, and biometrics capabilities to conduct your trial within both healthy volunteers and patient populations.
- Asset Development Consulting In-depth scientific expertise across disciplines.
- Clinical Pharmacology We help design a protocol that works harder and smarter for you.
- Adaptive Pharmaceutical Services A one stop drug development solution that is perfectly suited for early phase trials with shorter timelines.
- Bioanalytical and Biomarker Laboratories Supporting rapid in-house simple analysis with method development, assay validation and specimen analysis.
- Clinical Research Units Network of ICON-owned clinics with the ability to deliver the most complex of healthy volunteer, patient, or hybrid first-in-human and proof-of-concept studies.
- Biometrics Specialised data management, programming, biostatistics and medical writing services
- Early Phase Patient Studies Customised solutions designed to evaluate clinical endpoints and biomarkers within a smaller sample of patients to provide you with reliable proof of concept data.
- Quantitative Pharmacology and Pharmacometrics Expert clinical and nonclinical pharmacokinetic, pharmacodynamic, and exposure response data analysis services.
- Healthy Volunteer Recruitment Flexible volunteer recruitment solutions designed to serve the needs of your early phase clinical trial.
Asset Development Consulting
In-depth scientific expertise across disciplines.
Clinical Pharmacology
We help design a protocol that works harder and smarter for you.
Adaptive Pharmaceutical Services
A one stop drug development solution that is perfectly suited for early phase trials with shorter timelines.
Bioanalytical and Biomarker Laboratories
Supporting rapid in-house simple analysis with method development, assay validation and specimen analysis.
Clinical Research Units
Network of ICON-owned clinics with the ability to deliver the most complex of healthy volunteer, patient, or hybrid first-in-human and proof-of-concept studies.
Biometrics
Specialised data management, programming, biostatistics and medical writing services
Early Phase Patient Studies
Customised solutions designed to evaluate clinical endpoints and biomarkers within a smaller sample of patients to provide you with reliable proof of concept data.
Quantitative Pharmacology and Pharmacometrics
Expert clinical and nonclinical pharmacokinetic, pharmacodynamic, and exposure response data analysis services.
Healthy Volunteer Recruitment
Flexible volunteer recruitment solutions designed to serve the needs of your early phase clinical trial.
Our dedicated early clinical experts have the experience to address the most demanding early phase drug development challenges including:
Increasing complexity of trials
Delivery of reliable safety and efficacy data faster
Finding the right clinical settings to support complex assessment
Early phase challenges for biotechs
This whitepaper explores the growing challenges facing biotech during early phase drug development, and how these can be navigated to ensure the best possible outcomes.
_1.jpeg?crop=yes&w=2048&h=1251&a=0,0&itok=11XB_e-7 "survey report"){kind=icon}
ICON survey report: Early phase development - understanding key obstacles for biotechs in 2024
ICON conducted a survey of 149 small and medium biotechs to understand the challenges they are currently experiencing in early phase drug development.
In the latest ISR Phase 1 CRO benchmarking survey ICON outperforms other large CROs in 16 of the 17 operational metrics, with a significant lead differential in 11. We received our highest performance ratings on data quality, operational excellence, technology for real-time access to data, and patient/volunteer recruitment. Overall satisfaction with ICON for Phase 1 services has remained at last year’s all-time high and is amongst the very best of the large CROs. These results reflect our commitment to providing the very best early clinical drug development solutions.